hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06353399 id: 23.0366 briefTitle: Guided Bone Regeneration With and Without the Use of Intra-marrow Penetrations overallStatus: RECRUITING date: 2023-06-15 date: 2024-06-30 date: 2024-12-31 date: 2024-04-09 date: 2024-04-09 name: University of Louisville class: OTHER briefSummary: The primary aims of this study are to compare, after 6 months, the clinical and histologic results of intra-marrow penetrations vs no intra-marrow penetrations when performing guided bone regeneration procedures. conditions: Ridge Augmentation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: The study involves an investigator (surgeon) and an examiner. The examiner measures the clinical parameters before and after surgery and is blinded to the surgical procedure and if intra-marrow penetrations are utilized. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Intra-marrow penetrations name: No Intra-marrow penetrations measure: Alveolar Ridge Width measure: Alveolar Ridge Height measure: Buccal Soft Tissue Thickness measure: Histomorphometric Measurements sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Louisville status: RECRUITING city: Louisville state: Kentucky zip: 40202 country: United States name: Bindu Dukka, BDS, MSD, MPH role: CONTACT phone: 502- 852- 1817 email: himabindu.dukka@louisville.edu name: Niti Patel, DMD role: CONTACT phone: 859-685-5423 email: niti.patel@louisville.edu name: Bindu Dukka, BDS, MSD, MPH role: PRINCIPAL_INVESTIGATOR lat: 38.25424 lon: -85.75941 facility: University of Louisville status: RECRUITING city: Louisville state: Kentucky zip: 40202 country: United States name: Himabindu Dukka, BDS, MSD role: CONTACT lat: 38.25424 lon: -85.75941 hasResults: False
nctId: NCT06353386 id: 5684-01A id: MK-5684-01A type: OTHER domain: Merck id: 2023-506288-33 type: REGISTRY domain: EU CT id: U1111-1292-6912 type: OTHER domain: UTN briefTitle: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) overallStatus: NOT_YET_RECRUITING date: 2024-05-10 date: 2028-03-31 date: 2028-03-31 date: 2024-04-09 date: 2024-04-29 name: Merck Sharp & Dohme LLC class: INDUSTRY name: Orion Corporation, Orion Pharma briefSummary: Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01).
This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for the opevesostat-based treatment combinations. There will be no hypothesis testing in this study. conditions: Prostatic Neoplasms, Castration-Resistant studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 220 type: ESTIMATED name: Opevesostat name: Olaparib name: Docetaxel name: Cabazitaxel measure: Number of participants who experience one or more dose-limiting toxicities (DLTs) measure: Number of participants who experience one or more adverse events (AEs) measure: Number of participants who discontinue study intervention due to an AE measure: Prostate-specific antigen (PSA) response rate measure: Objective response rate (ORR) measure: Radiographic progression-free survival (rPFS) measure: Overall survival (OS) measure: Duration of response (DOR) measure: Time to first subsequent anticancer therapy (TFST) measure: Time to pain progression (TTPP) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06353373 id: HZKY-PJ-2024-7 briefTitle: Smart Technology Facilitated Venous Thromboembolism Prophylaxis Based on Bundled Evidence-based Prevention Strategies acronym: SmaVTE-BEST overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2025-02-28 date: 2025-02-28 date: 2024-04-09 date: 2024-04-09 name: Navy General Hospital, Beijing class: OTHER briefSummary: Venous thromboembolism (VTE) is the third leading cause of cardiovascular disease deaths globally, and its incidence is increasing over the years. Hospital-acquired VTE accounts for approximately 75% of all deaths attributed to VTE. However, only half of patients with indications for VTE prophylaxis take preventive measures, and high rates of inappropriate VTE prophylaxis prescribing contribute to the gap between VTE prophylaxis and guidelines. To further minimize the gap between clinical practice and guidelines, a range of strategies have been employed across various fields of VTE prophylaxis. One of the most effective measures is the utilization of a Clinical Decision Support System (CDSS). Smart technology-based CDSS facilitates automated evaluation of VTE risk and detection, addressing issues at both the beginning and end of the in-hospital VTE prevention process. but there is still a lack of research on how to effectively implement evidence-based VTE prophylaxis in the middle of the process.
In our hospital, routine use of DeVTEcare system (a CDSS for VTE risk assessment and integrated care) for in-hospital management of VTE has been launched since 2021. This study aims to investigate the effect of integrating bundled guideline-based VTE prevention strategies into the DeVTEcare system on in-hospital VTE prophylaxis. conditions: Venous Thromboembolism conditions: Clinical Decision Support Systems conditions: Digital Health studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 15626 type: ESTIMATED name: Application of the modified DeVTEcare system measure: In-hospital VTE measure: Guideline-compliant prescription of VTE prophylaxis measure: Preventable VTE measure: Hospital-related VTE death measure: Major bleeding measure: Non-major bleeding sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06353360 id: HL-06 briefTitle: TTField in Combination With TMZ and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma. overallStatus: NOT_YET_RECRUITING date: 2024-04-05 date: 2025-07-15 date: 2026-03-09 date: 2024-04-09 date: 2024-04-09 name: Jiangsu Healthy Life Innovation Medical Technology Co., Ltd class: INDUSTRY briefSummary: The goal of this clinical trial is To investigate the safety and efficacy of Tumor-Treating Fields (TTFields) in combined with temozolomide (TMZ) and tislelizumab in the treatment of newly diagnosed glioblastoma (GBM). conditions: Glioblastoma Multiforme studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Tumor Treating Fields name: Tislelizumab name: Temozolomide (TMZ) measure: Progression-Free Survival (PFS) measure: Number of participants with adverse events (AEs) measure: Objective response rate (ORR) measure: Disease control rate (DCR) measure: Overall Survival (OS) measure: PFS rate at 6 months measure: PFS rate at 1 year measure: OS rate at 1-year sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06353334 id: 2024-3-22-8 briefTitle: Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial) overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-12-31 date: 2025-12-31 date: 2024-04-09 date: 2024-04-09 name: Tang Ziren class: OTHER briefSummary: Butylphthalide (NBP) is a neuroprotective medication capable of ameliorating neurological dysfunction induced by ischemia, hypoxia, and reperfusion injury in the brain. However, evidence regarding the improvement of neurological function prognosis in patients with return of spontaneous circulation (ROSC) after cardiac arrest (CA) by NBP is limited. This study aims to evaluate the safety and efficacy of NBP treatment in improving the neurological function prognosis of patients with ROSC after CA.The study will be a single-center, randomized, double-blind, placebo-controlled trial. The sample size is estimated to be 100 patients. Eligible patients will be randomly allocated in a 1:1 ratio to receive either NBP or placebo treatment daily for a duration of 14 days. The initial administration of NBP or placebo treatment will commence within 6 hours after ROSC following CA. The primary outcome is the proportion of patients with Cerebral Performance Category (CPC) scores of 1-2 at 90 days after randomization in each group. The primary safety outcome is the percentage of severe adverse events occurring during the 14-day treatment period. This trial will determine the efficacy of NBP in providing neuroprotective effects for patients with ROSC after CA. conditions: Butylphthalide conditions: Cardiac Arrest conditions: Neuroprotective Drugs studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Butylphthalide and Sodium Chloride Injection name: Saline Solution measure: The proportion of patients with a CPC score of 1-2 sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Chao-Yang Hospital city: Beijing state: Beijing zip: 100020 country: China name: Xingsheng Wang, M.D role: CONTACT phone: +86 15265386100 email: wangxingsheng1995@163.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06353321 id: STU-2024-0024 briefTitle: Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1 overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-10-01 date: 2025-10-01 date: 2024-04-09 date: 2024-04-09 name: University of Texas Southwestern Medical Center class: OTHER name: RefleXion Medical briefSummary: To qualitatively determine the imaging performance of PET-CT imaging subsystem of the RefleXion X1 System Device in patients undergoing standard-of-care (SOC) \[68Ga\]-PSMA-11 PET-CT using Illuccix on the same day. conditions: Prostate Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 25 type: ESTIMATED name: PET-CT imaging subsystem of the RefleXion X1 System Device measure: Qualitative assessment of RefleXion X1 imaging performance with Illuccix PSMA PET imaging agent immediately following a standard of care Illuccix PET/CT sex: MALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06353308 id: EA230308 briefTitle: Effectiveness of an Online Intervention Using a Feminist Approach on Gender Equality Promotion and Sexual Violence Prevention in China overallStatus: COMPLETED date: 2023-05-12 date: 2024-02-10 date: 2024-03-02 date: 2024-04-09 date: 2024-04-09 name: The University of Hong Kong class: OTHER briefSummary: This paper presents the findings of a clustered randomized controlled trial (cRCT) that evaluated the effectiveness of an online feminist sexual health intervention among Chinese young adults, providing insights into the impacts of this innovative approach and contribute to the growing body of literature on feminist interventions for sexual health and equality promotion. conditions: Sexual Violence studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 422 type: ACTUAL name: Sexual Violence Prevention name: Sexual health intervention measure: Rape myth acceptance measure: Sociocultural Attitudes toward Appearance measure: Sexual Attitudes Scale measure: Sexual Desire Inventory sex: ALL minimumAge: 18 Years maximumAge: 29 Years stdAges: ADULT facility: The university of Hong Kong city: Hong Kong zip: 000000 country: Hong Kong lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06353295 id: 22-38098 id: CO-US-412-6436 type: OTHER_GRANT domain: Gilead Sciences briefTitle: Community-based, Peer-delivered PrEP for Female Sex Workers in Rural Uganda: The Peers for PrEP (P4P) Study acronym: P4P overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-06 date: 2025-06 date: 2024-04-09 date: 2024-04-09 name: University of California, San Francisco class: OTHER name: Gilead Sciences briefSummary: The overall goal of the P4P: Peers for PrEP (pre-exposure prophylaxis) study is to pilot test a peer-led and delivered intervention for biomedical HIV prevention that is tailored to women who engage in sex work in southwestern Uganda. This study will evaluate whether this intervention is feasible, acceptable, and increases uptake of biomedical prevention. conditions: HIV/AIDS studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A single-arm pilot trial to evaluate a community-based, peer-led and delivered intervention to provide biomedical prevention products (e.g. pre-exposure prophylaxis \[PrEP\] and post-exposure prophylaxis \[PEP\]) for women who engage in sex work in southwestern Uganda. This study will test whether the intervention is feasible, acceptable, and increases biomedical prevention uptake. primaryPurpose: PREVENTION masking: NONE count: 140 type: ESTIMATED name: P4P intervention measure: Uptake of biomedical prevention measure: Feasibility of delivery of the P4P intervention by peers measure: Acceptability of the P4P intervention sex: FEMALE minimumAge: 15 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Infectious Diseases Research Collaboration city: Kampala country: Uganda name: Jane Kabami, MPH, PhDc role: CONTACT phone: +256 312 281-479 email: jkabami@idrc-uganda.org lat: 0.31628 lon: 32.58219 hasResults: False
nctId: NCT06353282 id: 24-000795 briefTitle: MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents overallStatus: NOT_YET_RECRUITING date: 2025-07-01 date: 2026-01-31 date: 2026-12-31 date: 2024-04-09 date: 2024-04-09 name: University of California, Los Angeles class: OTHER briefSummary: The primary objective of this study is to determine the safety and feasibility of 3,4-methylenedioxymethamphetamine (MDMA) -assisted psychotherapy to treat resistant post-traumatic stress disorder (PTSD). The secondary objectives are the exploration of effectiveness for treatment-resistant PTSD, symptoms of depression, and anxiety symptoms. conditions: PTSD, Post Traumatic Stress Disorder conditions: Adolescents conditions: Psychotherapy studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: MDMA name: Psychotherapy measure: Changes in heart rhythm via Carnation Ambulatory Heart Monitor measure: Changes in blood pressure measure: Change in pulse measure: Change in body temperature measure: Mean change in score of visual analog scale to assess potential for misuse of MDMA measure: Mean change in PTSD symptom severity via the Child PTSD Symptom Scale measure: Mean change in PTSD symptom severity via the Clinician-Administered PTSD Scale (CAPS-CA-5) measure: Mean change in depression symptom severity via the Patient Health Questionnaire-9 (PHQ-9). measure: Mean change in anxiety symptom severity via the Generalized Anxiety Disorder 7-item (GAD-7) sex: ALL minimumAge: 16 Years maximumAge: 17 Years stdAges: CHILD facility: UCLA Semel Institute for Neuroscience and Human Behavior city: Los Angeles state: California zip: 90095 country: United States name: Jessica K Jeffrey, MD, MPH, MBA role: CONTACT phone: 310-825-5263 email: jjeffrey@mednet.ucla.edu name: Marc J Weintraub, Ph.D. role: CONTACT phone: 310-825-1300 email: mjweintraub@mednet.ucla.edu name: Jessica K Jeffrey, MD, MPH, MBA role: PRINCIPAL_INVESTIGATOR lat: 34.05223 lon: -118.24368 hasResults: False
nctId: NCT06353269 id: 4255 briefTitle: Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections overallStatus: RECRUITING date: 2024-04 date: 2027-01 date: 2027-10 date: 2024-04-09 date: 2024-04-09 name: University of California, Irvine class: OTHER briefSummary: * The goal of this clinical trial is to learn about medication adherence to difference types of vaginal estrogen in women with low levels of estrogen (for example, post-menopausal women) who have recurrent urinary tract infections. Medication adherence means whether patients take their medicine as prescribed.
* These tests will then be repeated at 6 months to assess if vaginal estrogen treatment causes changes to the vagina. conditions: Recurrent Urinary Tract Infection conditions: Hypoestrogenism studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 111 type: ESTIMATED name: Estring Vaginal Product name: Vagifem name: Estrace 0.01% Vaginal Cream measure: Adherence to vaginal estrogen treatment measure: UTI rates measure: validated patient questionnaire - Urinary Distress Inventory Short Form (UDI-6) measure: validated patient questionnaires - UTI Symptoms Assessment Questionnaire (UTISA) measure: validated patient questionnaires - Treatment Satisfaction with Medications Questionnaire (SATMED-Q) measure: validated patient questionnaires - Patient Global Impression of Improvement Questionnaire (PGI-I) measure: validated patient questionnaires - Medication Adherence Report Scale (MARS-5) measure: optical coherence tomography measurements for nested OCT cohort - vaginal epithelial thickness measure: optical coherence tomography measurements for nested OCT cohort - blood vessel density measure: Vaginal health index for nested microbiome cohort measure: Vaginal maturation index for nested microbiome cohort measure: Urologic microbiome results for nested microbiome cohort measure: Vaginal microbiome results for nested microbiome cohort sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of California Irvine Medical Center status: RECRUITING city: Orange state: California zip: 92868 country: United States name: CHARLOTTE TER HAAR role: CONTACT email: terhaarc@hs.uci.edu lat: 33.78779 lon: -117.85311 hasResults: False
nctId: NCT06353256 id: 300012607 id: UL1TR003096 type: NIH link: https://reporter.nih.gov/quickSearch/UL1TR003096 id: 24POST1198805 type: OTHER_GRANT domain: American Heart Association briefTitle: A Community Health Worker Intervention to Address Preeclampsia acronym: AW2H overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-04-30 date: 2025-04-30 date: 2024-04-09 date: 2024-04-09 name: University of Alabama at Birmingham class: OTHER name: American Heart Association name: National Center for Advancing Translational Sciences (NCATS) briefSummary: United States maternal mortality and preterm birth rates are among the highest among high-income countries due in part to a combination of racial, regional and socioeconomic disparities in access to care and overall health. The research proposed focuses on adapting and expanding a perinatal community health worker intervention for Black postpartum patients with preeclampsia (PE). Investigators will partner with a community-based organization that trains and deploys community health workers. Investigators will test an intervention for urban and rural Black postpartum patients with PE to 1) enhance blood pressure control postpartum and 2) promote long-term cardiovascular disease prevention for this underserved population. This pilot study will determine if randomizing and implementing a community health worker intervention tailored to pregnant people experiencing preeclampsia is feasible and found to be acceptable by participants. conditions: Preeclampsia Postpartum studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: usual postpartum care measure: Acceptability sex: FEMALE minimumAge: 16 Years maximumAge: 56 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06353243 id: STUDY00022901 briefTitle: Bilateral Infant Stimulation Study acronym: BLISS overallStatus: RECRUITING date: 2024-02-26 date: 2024-08 date: 2024-08 date: 2024-04-09 date: 2024-04-09 name: Oregon Health and Science University class: OTHER briefSummary: This study will investigate stress that parents of children admitted to the neonatal intensive care unit (NICU) experience. Investigation of a novel intervention of using bilateral alternating stimulation to reduce parental stress and anxiety and increase bonding/attachment in NICU. Evaluate parental stress and feelings of bonding using surveys before and after the intervention. Intervention will be done at neonate's bedside while admitted to the NICU. Vital sign data will be collected as a marker of parent and neonate's stress response during the intervention. conditions: Parent-Child Relations conditions: Preterm Birth conditions: Stress Reaction conditions: Hospitalism in Children studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 40 type: ESTIMATED name: Bilateral alternating stimulation measure: Parental anxiety measure: Physiologic stress response measure: Parental distress sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Oregon Health and Science University Neonatal Intensive Care Unit status: RECRUITING city: Portland state: Oregon zip: 97219 country: United States name: Emily Garavatti, MD role: CONTACT phone: 503-494-2634 email: garavatt@ohsu.edu lat: 45.52345 lon: -122.67621 hasResults: False
nctId: NCT06353230 id: 0001 briefTitle: Comparison of Sclerotherapy Agents Used for Rectal Prolapse Treatment in Children acronym: Prolapse overallStatus: COMPLETED date: 2019-10-15 date: 2020-10-14 date: 2021-04-13 date: 2024-04-09 date: 2024-04-15 name: King Edward Medical University class: OTHER briefSummary: Introduction Patients with rectal prolapse are treated with injection sclerotherapy, which is the most often used first-line surgical technique. Injection sclerotherapy has a success rate of 90-100% in youngsters, according to certain studies. Objective To compare the outcome of injection sclerotherapy using 5% Phenol in almond oil, 15% hypertonic saline and 50% dextrose water in the treatment of rectal prolapse in children. conditions: Rectal Prolapse studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Comparison of 5% phenol in almond oil, 15% hypertonic saline and 50% dextrose water for sclerotherapy treatment of rectal prolapse in children. primaryPurpose: TREATMENT masking: NONE maskingDescription: Randomly allocated groupA,B or C by computer generated lottery method.and participants ,care provider and outcome assessor were kept blind by removing the drug name from injection vial count: 93 type: ACTUAL name: injection 5% phenol in almond oil name: injection 15% hypertonic saline name: injection 50% dextrose water measure: Recurrence measure: fecal incontinence sex: ALL minimumAge: 3 Years maximumAge: 13 Years stdAges: CHILD facility: department of pediatric surgery King Edward Medical University city: Lahore state: Punjab zip: 54000 country: Pakistan lat: 31.558 lon: 74.35071 hasResults: False